U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H27FO6
Molecular Weight 394.4347
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRIAMCINOLONE

SMILES

C[C@@]12C=CC(=O)C=C2CC[C@@]3([H])[C@]4([H])C[C@]([H])([C@](C(=O)CO)([C@@]4(C)C[C@@]([H])([C@@]31F)O)O)O

InChI

InChIKey=GFNANZIMVAIWHM-OBYCQNJPSA-N
InChI=1S/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13-,14-,15+,16-,18-,19-,20-,21-/m0/s1

HIDE SMILES / InChI

Molecular Formula C21H27FO6
Molecular Weight 394.4347
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/19744340 http://www.drugbank.ca/drugs/DB00620

Triamcinolone is a long-acting synthetic corticosteroid primarily used for their anti-inflammatory effects in disorders of many organ systems. Triamcinolone diacetate injectable suspension is indicated for intramuscular use as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiform (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency, congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate ant tuberculous chemotherapy. For palliative management of leukemia’s and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate ant tuberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. As adjunctive therapy for short-term administration in acute gouty arthritis; acute rheumatic carditis. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins that, through inhibition of arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Firstly, however, these glucocorticoids bind to the glucocorticoid receptors, which translocate into the nucleus, bind DNA (GRE), and change genetic expression both positively and negatively. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.5 nM [IC50]
Target ID: P04150
Gene ID: 2908.0
Gene Symbol: NR3C1
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
ARISTOCORT

Approved Use

is indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).

Launch Date

-3.81196796E11
Palliative
ARISTOCORT

Approved Use

is indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).

Launch Date

-3.81196796E11
Palliative
ARISTOCORT

Approved Use

is indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).

Launch Date

-3.81196796E11
Palliative
ARISTOCORT

Approved Use

is indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).

Launch Date

-3.81196796E11
Palliative
ARISTOCORT

Approved Use

is indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).

Launch Date

-3.81196796E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7202 ng/mL
4 mg single, ocular
dose: 4 mg
route of administration: Ocular
experiment type: SINGLE
co-administered:
TRIAMCINOLONE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1911 ng × h/mL
4 mg single, ocular
dose: 4 mg
route of administration: Ocular
experiment type: SINGLE
co-administered:
TRIAMCINOLONE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
18.7 day
4 mg single, ocular
dose: 4 mg
route of administration: Ocular
experiment type: SINGLE
co-administered:
TRIAMCINOLONE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
120 mg 1 times / day multiple, intramuscular
Higher than recommended
Dose: 120 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 120 mg, 1 times / day
Sources: Page: p.588
unhealthy, 28-57
n = 12
Health Status: unhealthy
Condition: Asthma
Age Group: 28-57
Sex: M+F
Population Size: 12
Sources: Page: p.588
360 mg single, intramuscular
Highest studied dose
Dose: 360 mg
Route: intramuscular
Route: single
Dose: 360 mg
Sources: Page: p.1465
unhealthy, 37.5
n = 6
Health Status: unhealthy
Condition: Asthma
Age Group: 37.5
Sex: M+F
Population Size: 6
Sources: Page: p.1465
200 mg single, intrabursal
Overdose
Dose: 200 mg
Route: intrabursal
Route: single
Dose: 200 mg
Sources: Page: p.13
unhealthy, 46
n = 1
Health Status: unhealthy
Condition: Bursitis
Age Group: 46
Sex: F
Population Size: 1
Sources: Page: p.13
Disc. AE: Cushing's syndrome...
AEs leading to
discontinuation/dose reduction:
Cushing's syndrome
Sources: Page: p.13
AEs

AEs

AESignificanceDosePopulation
Cushing's syndrome Disc. AE
200 mg single, intrabursal
Overdose
Dose: 200 mg
Route: intrabursal
Route: single
Dose: 200 mg
Sources: Page: p.13
unhealthy, 46
n = 1
Health Status: unhealthy
Condition: Bursitis
Age Group: 46
Sex: F
Population Size: 1
Sources: Page: p.13
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
weak
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
likely (co-administration study)
Comment: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects. Co-administration of other strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin, cobicistat-containing products) with Kenalog-10 Injection may cause increased plasma concentration of triamcinolone leading to adverse reactions.
Page: 10.0
PubMed

PubMed

TitleDatePubMed
[Experiences with liposuction of established surgeons].
2001
Should inhaled corticosteroids be used in the long term treatment of chronic obstructive pulmonary disease?
2001
Clinical prescribing of allergic rhinitis medication in the preschool and young school-age child: what are the options?
2001
Antibacterial activity of apical surface fluid from the human airway cell line Calu-3: pharmacologic alteration by corticosteroids and beta(2)-agonists.
2001 Aug
[Relevance of nerve blocks in treating and diagnosing low back pain--is the quality decisive?].
2001 Dec
Injections and surgical therapy in chronic pain.
2001 Dec
Cost analysis of the use of inhaled corticosteroids in the treatment of asthma: a 1-year follow-up.
2001 Dec
Therapeutic efficacy of selective nerve root blocks in the treatment of lumbar radicular leg pain.
2001 Feb 10
Triamcinolone: new and old indications.
2001 Jul
Necrobiosis lipoidica in a 9-year-old girl with new-onset type II diabetes mellitus.
2001 Jul-Aug
A minimally invasive approach for treating postoperative seromas after incisional hernia repair.
2001 Jul-Sep
Tonsillar fossa steroid injection for reduction of the post-tonsillectomy pain.
2001 Jun
Pain-relieving effect of local steroid injection in uvulopalatopharyngoplasty.
2001 Jun
Steroid allergy: report of two cases.
2001 Jun
Pneumocephalus after cervical epidural steroid injection.
2001 Jun
Melasma treated with hydroquinone, tretinoin, and a fluorinated steroid.
2001 Mar
Investigation of some commercially available spacer devices for the delivery of glucocorticoid steroids from a pMDI.
2001 May
Plasma cell mucositis.
2001 Nov
Induction of the epithelial Na+ channel via glucocorticoids in mineralocorticoid receptor knockout mice.
2001 Nov
Apoptosis of airway epithelial cells induced by corticosteroids.
2001 Nov 15
Safety of steroid injections in the treatment of nasofrontal recess obstruction.
2001 Nov-Dec
Papular elastorrhexis in childhood improved by intralesional injections of triamcinolone.
2001 Oct
Cushing syndrome induced by serial occipital nerve blocks containing corticosteroids.
2001 Oct
Exacerbation of allergic contact dermatitis from amcinonide triggered by patch testing.
2001 Oct
Experience with difficult keloids.
2001 Oct
Tumescent steroid infiltration to reduce postoperative swelling after craniofacial surgery.
2001 Oct
Treatment of childhood phimosis with a moderately potent topical steroid.
2001 Sep
Lichenoid sarcoidosis in a 3-year-old girl.
2001 Sep-Oct
Deposition and pharmacokinetics of an HFA formulation of triamcinolone acetonide delivered by pressurized metered dose inhaler.
2001 Summer
Two cases of morphea associated with Hashimoto's thyroiditis.
2002
Topical steroid therapy for phimosis.
2002 Apr
Intralesional triamcinolone for chondrodermatitis nodularis: a follow-up study of 60 patients.
2002 Apr
Localized linear scleroderma with cutaneous calcinosis.
2002 Feb
Posterior retinal vasculitis associated with multiple sclerosis.
2002 Feb
Intralesional corticosteroids as an alternative treatment for central giant cell granuloma.
2002 Feb
Subcutaneous steroid injection as treatment for chalazion: prospective case series.
2002 Feb
Subtenon's depot corticosteroid injections in patients with a history of corticosteroid-induced intraocular pressure elevation.
2002 Feb
Shoulder joint capsule distension (hydroplasty): a case series of patients with "frozen shoulders" treated in a primary care office.
2002 Jan
Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis.
2002 Jan
The effect of corticosteroids on pleurodesis induced by doxycycline in rabbits.
2002 Jan
Glucocorticoid epidural for sciatica: metabolic and endocrine sequelae.
2002 Jan
Stopping triamcinolone led to treatment failures in patients with persistent asthma who were receiving salmeterol and triamcinolone.
2002 Jan-Feb
Correction of the soft tissue pollybeak using triamcinolone injection.
2002 Jan-Mar
Intravitreal triamcinolone in recurrence of choroidal neovascularisation.
2002 Jun
Multiple-center study of reduced-concentration triamcinolone topical solution for the treatment of dogs with known or suspected allergic pruritus.
2002 Mar
CD30-positive T-cell-rich pseudolymphoma induced by gold acupuncture.
2002 May
Intravitreal triamcinolone for refractory diabetic macular edema.
2002 May
Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration.
2002 May
Local injection treatment for lateral epicondylitis.
2002 May
Systemic effect comparisons of six inhaled corticosteroid preparations.
2002 May 15
Patents

Sample Use Guides

The initial intramuscular dosage of triamcinolone diacetate injectable suspension may vary from 3 to 48 mg per day depending on the specific disease entity being treated
Route of Administration: Intramuscular
Unknown
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:12:07 UTC 2021
Edited
by admin
on Fri Jun 25 21:12:07 UTC 2021
Record UNII
1ZK20VI6TY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TRIAMCINOLONE
EP   GREEN BOOK   HSDB   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
INN  
Official Name English
TRIAMCINOLONE [EP MONOGRAPH]
Common Name English
TRIAMCINOLONE ACETONIDE IMPURITY A [EP]
Common Name English
TRIAMCINOLONE [MART.]
Common Name English
TRIAMCINOLONE [VANDF]
Common Name English
TRIAMCINOLONE [HSDB]
Common Name English
9-FLUORO-11,BETA,,16.ALPHA.,17,21-TETRAHYDROXYPREGNA-1,4-DIENE-3,20-DIONE
Common Name English
TRIAMCINOLONE [INN]
Common Name English
NSC-13397
Code English
TRIAMCINOLONE [WHO-DD]
Common Name English
TRIAMCINOLONE [USP-RS]
Common Name English
TRIAMCINOLONE [ORANGE BOOK]
Common Name English
KENACORT
Brand Name English
TRIAMCINOLONE [MI]
Common Name English
PREGNA-1,4-DIENE-3,20-DIONE, 9-FLUORO-11,16,17,21-TETRAHYDROXY-, (11.BETA.,16.ALPHA.)
Common Name English
TRIAMCINOLONE [GREEN BOOK]
Common Name English
TRIAMCINOLONE [USP]
Common Name English
ARISTOCORT
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C521
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
WHO-VATC QH02AB08
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
WHO-VATC QA01AC01
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
WHO-ATC D07BB03
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
LIVERTOX 994
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
WHO-ATC R03BA06
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
CFR 21 CFR 524.1600B
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
CFR 21 CFR 522.2483
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
WHO-VATC QR01AD11
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
NDF-RT N0000175450
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
WHO-VATC QD07AB09
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
WHO-ATC A01AC01
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
CFR 21 CFR 524.2483
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
WHO-ATC D07XB02
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
WHO-ATC R01AD11
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
WHO-ATC H02AB08
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
NDF-RT N0000175576
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
CFR 21 CFR 524.2482
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
WHO-VATC QD07CB01
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
CFR 21 CFR 524.1600A
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
WHO-VATC QD07BB03
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
WHO-VATC QD07XB02
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
WHO-ATC S02CA04
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
WHO-VATC QC05AA12
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
CFR 21 CFR 520.2483
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
WHO-VATC QR03BA06
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
WHO-ATC D07CB01
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
WHO-VATC QS01BA05
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
WHO-VATC QS02CA04
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
WHO-ATC S01BA05
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
WHO-ATC C05AA12
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
WHO-ATC D07AB09
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C901
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
PRIMARY
DRUG CENTRAL
2725
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
PRIMARY
INN
755
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
PRIMARY
WIKIPEDIA
TRIAMCINOLONE
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
PRIMARY
LACTMED
Triamcinolone, Topical
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
PRIMARY
DRUG BANK
DB00620
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
PRIMARY
CAS
124-94-7
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
PRIMARY
MERCK INDEX
M11027
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
PRIMARY Merck Index
IUPHAR
2870
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
PRIMARY
EVMPD
SUB11251MIG
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
PRIMARY
ChEMBL
CHEMBL1451
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
PRIMARY
LACTMED
Triamcinolone
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
PRIMARY
RXCUI
10759
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
PRIMARY RxNorm
PUBCHEM
31307
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
PRIMARY
EPA CompTox
124-94-7
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
PRIMARY
FDA UNII
1ZK20VI6TY
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
PRIMARY
HSDB
3194
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
PRIMARY
ECHA (EC/EINECS)
204-718-7
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
PRIMARY
MESH
D014221
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
PRIMARY
USP_CATALOG
1676000
Created by admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
PRIMARY USP-RS
Related Record Type Details
TRANSPORTER -> SUBSTRATE
TARGET -> AGONIST
Related Record Type Details
PARENT -> IMPURITY
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY